Navigation Links
BioCryst Announces Partnerships for Peramivir for Influenza Outside the U.S.
Date:9/15/2009

BIRMINGHAM, Ala., Sept. 15 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S. Each partner will immediately begin meeting with key government officials in their respective territories to discuss peramivir's availability during this global health emergency.

BioCryst's new partners include:

  • moksha8 Pharmaceuticals, Inc. for Brazil and Mexico

moksha8 Pharmaceuticals, Inc. has established broad commercial operations in Brazil and Mexico, the two key countries in Latin America that represent 75% of the $30 billion Latin America pharmaceutical market. The Company is currently selling over $200 million of products in the anti-infectives, central nervous system and inflammation indications under partnerships with Roche and Pfizer. Products in the Company's portfolio include key brands such as Rocephin, Bactrim, Lexotan and Rivotril.

  • NT Pharma (Group) Co., Ltd. for China

NT Pharma was established in 1995 and has over 1,000 employees, corporate offices in Hong Kong and sales and marketing subsidiaries in Shanghai, Beijing, Guangzhou, Suzhou, Taizhou and Hainan for the distribution of pharmaceutical products including prescription medicine and vaccines. In 2009, the Group expects to achieve sales revenue of RMB 3 billion (U.S.$440 million), with a nationwide network that covers more than 100 cities, 1,500 hospital
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. BioCryst Executives to Present at Two Investor Conferences
2. BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
3. BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
4. BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
6. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
7. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
8. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
9. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
10. avVaa World Health Care Products, Inc. Announces DRTV Test Results
11. Building Healthier America Announces the High Five Program Addressing Factors Affecting the Energy Levels of Overweight Men

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ewswire-USNewswire/--AnarticlebyJanetWoodcock,M.D....rch,titled"ADifficultBalance-PainManagement,DrugSa...ewEnglandJournalofMedicine. ,, (Logo: http://ww..., Inthearticle,WoodcockdiscussesFDAeffortstostrike...editandmanagingtherisksposedbyvariousanalgesics.As...
(Date:11/25/2009)... cancer who were treated with cisplatin-based chem...eurological side effects and Raynaud-like phenomen..., according to a new study published online Novemb...tute . , Marianne Brydy, M.D., of the Department...rgen, Norway, and colleagues conducted a cross-sec...
(Date:11/25/2009)...short to draw definite conclusions, experts say, ...-- In diabetic patients with blocked coronary arte...s at one year whether patients undergo bypass surg...ers report. , Bypass surgery has been the stand...artery disease. However, less invasive approaches ...
(Date:11/25/2009)...ical symptoms, study finds , , WEDNESDA...ffects are among the potential problems faced by l...reated with cisplatin-based chemotherapy, a new st...gian men treated for unilateral testicular cancer ... survey conducted from 1998 to 2002. , The rese...
(Date:11/25/2009)...the4thStraightYear ,, WASHINGTON,Nov.25/PRNew...gia(LCA-GA)issuedthe 4thAnnualReportCardonLungCanc...instthislethaldiseaseinthestateofGeorgia.LCA-GAisa...ganizationdedicatedexclusivelytopatientsupportanda..., (Logo: http://www.newscom.com/cgi-bin/prnh/20...
Breaking Medicine News(10 mins):Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2
...of NewYork-Presbyterian Hospital and Columbia Univ...wo important new guidelines for treatment of HIV./...International AIDS Society--USA's (IAS-USA) recomm... the Aug. 16 Journal of the American Medical Assoc...
...mber at a Sydney maternity hospital was diagnosed ... families may have to be given antibiotics// as a ...at the women and babies facility of Royal Prince A...l contact with patients and families immediately,'...
... issued an advisory to parents not to give unpaste... including cider, fruit juices and raw milk// to t...ak immune systems are advised not to consume such ...o said that a majority of juice n the country was ...
...ducted in the US, scientists have claimed that a n... way the disease of prostate cancer is diagnosed a...st will be available to patients in 18 months, hav...pread. Researchers had explained that for ma...
...has been issued in Gujarat's flood-ravaged Surat c...us pulmonary syndrome - a disease that spreads thr...adly virus affects the kidneys, lungs, pulmonary s...ibility of contracting the virus is high. Vika...
... launched a 252 million pounds (Rs.21.94 million) ...ld health programme aimed at saving one million li... being provided through the Department for Interna...be spent over five years in support of the second ...
Other Medicine News:Health News:Dr. Scott Hammer Authors Two New Guidelines for HIV Treatment 2Health News:Breakthrough In Prostate Cancer Detection And Treatment 2
(Date:11/25/2009)...Nov.25/PRNewswire-USNewswire/--RemediumTechnologie...stopsseverebleeding,wonfirstprizeand$10,000intheMo...Challenge2009,companyofficialsannouncetoday. ,,...Remedium,steampitchedtheirinventionattheGSCSecurit...,, Remedium( www.remediumtechnologies.com )isde...
(Date:11/25/2009)....25/PRNewswire-Asia-FirstCall/--ChinaSkyOne,Medica... CSKI ),a,leadingfullyintegratedpharmaceuticalcomp...hePeople,sRepublicofChina("PRC"),today,announcedth...utefor,theControlofPharmaceuticalandBiologicalProd...sDiagnosticKitforHumanProstateSpecific,Antigen(Col...
(Date:11/25/2009)...,Nov.25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq:...of-carebloodanalysissystems,announcedtodaythatClin...sentatthe21stAnnualPiperJaffrayHealthCareConferenc...ncewillbeheldattheNewYorkPalaceHotelinNewYorkCity....uresandmarketsportablebloodanalysissystemsforusein...
Breaking Medicine Technology:Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Wellcome Trust funds dengue fever research in Leuven 10516 1Wellcome Trust funds dengue fever research in Leuven 10516 2Oklahoma scientists discover promising new path for treating traumas 60039 1Oklahoma scientists discover promising new path for treating traumas 60039 2CSHL led team discovers rare mutation dramatically increasing schizophrenia risk 10513 1CSHL led team discovers rare mutation dramatically increasing schizophrenia risk 10513 2
...Submission -, TAMPA, Fla., Oct. 25 Sirion Therap...iopharmaceutical company,announced positive prelim...-601) program, which evaluated the steroid,s poten...llowing ocular surgery. "We are very pleased with...al as a potent, well-tolerated steroid treatment f...
...ta presented by Dr. Peter Jones, Director of USC,s...AN FRANCISCO, Oct. 25 SuperGen Inc. (Nasdaq:,SUPG...very, rapid,development and commercialization of t...ancies, today announced as part of a series of,pre...l Conference that,S110, the Company,s decitabine-d...
Other Medicine Technology:Sirion Therapeutics Announces Positive Phase III Results for Difluprednate 2Sirion Therapeutics Announces Positive Phase III Results for Difluprednate 3Sirion Therapeutics Announces Positive Phase III Results for Difluprednate 4SuperGen's Novel Hypomethylating Agent Highlighted at AACR Plenary Session 2SuperGen's Novel Hypomethylating Agent Highlighted at AACR Plenary Session 3
Jewelers Forceps
Gill Curved Iris Forceps With Serrations
Gill Curved Iris Forceps
Osher Fixation Forceps
Medicine Products: